Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen


Koca ., Demir D., Ozdemir ., Akdeniz H. , Kurt .

Kafkas J Med Sci, cilt.7, ss.53-59, 2017 (Hakemli Üniversite Dergisi)

  • Cilt numarası: 7 Konu: 1
  • Basım Tarihi: 2017
  • Dergi Adı: Kafkas J Med Sci
  • Sayfa Sayıları: ss.53-59

Özet

Amaç: İlk-sıra tedavide oksaliplatin-temelli rejim alan metastatik
kolorektal kanserli (mKRK) hastalarda ikinci-sıra tedavide modifiye
FOLFIRI-Bevacizumab (mFOLFIRI-B) rejiminin etkinlik ve tolerabilitesi
araştırıldı.
Materyal ve Metot: Çalışmaya ilk-sıra tedavide oksaliplatin-temelli
rejim alan, ardından progresyon gözlenen ve ikinci-sıra tedavide
mFOLFIRI-B rejimi alan mKRK’li hastalar alındı. Toksisite ve etkinlik
ile ilgili veriler retrospektif olarak değerlendirildi.
Introduction
Colorectal cancer is a widespread and fatal disease.
While constituting approximately 10% of all cancers,
it is the third commonest malignancy in both genders
and is the third leading cause of death. It is responsible
of 10% of deaths due to cancer1,2. The main method of
therapy in colorectal cancers is surgical therapy. A part
of stage II patients and stage III patients are given adjuvant
chemotherapy (CT) following surgical treatment.
In stage IV patients, the main treatment approach is
systemic CT2–4. In rectal cancer, adjuvant or neoadjuvant
chemoradiotherapy (CRT) is added in addition
to these approaches5.
Metastatic colorectal cancer (mCRC) constitutes an
important part of all colorectal cancers6. Survival time
increases and symptoms related to the disease are controlled
with use of CT7–9. Currently, survival time has
increased to more then 2 years with new generation
CT drugs including oxaliplatin and irinotecan and
Bulgular: Toplam 172 mKRK’li hasta ikinci-sıra tedavide
mFOLFIRI-B rejimi almıştı. Hastaların %39,5’inde objektif cevap,
9,0 aylık (7,6 ile 10,3 arası) median progresyonsuz yaşam, 19,0 aylık
(15,1 ile 26,2 arası) median tüm yaşam saptandı. Grade 3/4 toksisite
%33,7 oranında tespit edildi. Grade 3/4 hematolojik toksisite
%31,9 oranında tespit edildi.
Sonuç: Sonuç olarak mKRK’li hastalarda oksaliplatin-temelli rejim
sonrası ikinci-sıra tedavide mFOLFIRI-B rejimi etkili ve güvenilir bir
tedavi rejimidir.

Aim: We aimed to investigate the efficacy and tolerability of modified
FOLFIRI-Bevacizumab (mFOLFIRI-B) regime in the secondline
treatment of metastatic colorectal cancer (mCRC) patients
who received oxaliplatin-based regimen in the first-line treatment.
Material and Method: The patients treated with mFOLFIRI-B
regimen in second-line therapy who had progressed after oxaliplatin-
based chemotherapy were included in this study. The datas of
toxicity and efficacy of the regimen were retrospectively evaluated.
Results: Total 172 mCRC patients had received mFOLFIRI-B regime
in the second-line treatment. 39.5% objective response rate,
9.0 months (7.6 to 10.3) median progression-free survival, 19.0
months (15.1 to 26.2) median overall survival were found. Grade
3/4 toxicity was observed in 33.7%. Grade 3/4 hematologic toxicity
was most frequently observed toxicity (31.9%).
Conclusion: mFOLFIRI-B is an efficient and safe regimen for the
second-line treatment of mCRC patients after the oxaliplatinbased
regimen.